However, in tandem with this move, the company has also secured access to an incubator space facility in New Brunswick, New Jersey where intramural laboratory-based research will be conducted. This facility will provide the necessary space to conduct ongoing work on both AVR118 as well as the new compounds recently acquired from Cetek Corporation, the company said.
As part of its strategy to reduce operating costs and strengthen its focus on new drug discovery, the company will outsource the manufacturing of its lead compound AVR118 to a contract manufacturer with the capability of producing commercial volumes of product under strict good manufacturing practice conditions.
The additions to the company’s product pipeline as well as the newly acquired drug discovery platform are featured on the new website.